Table 2 Characteristics of the systematic reviews/meta-analysis included in the umbrella review
From: Statin use and risk of HCC in patients with MASLD and T2DM: an umbrella review and meta-analysis
Study | Included studies | Years Searched | Study type(s) | Population | Chronic Systemic Disease | Conclusions |
|---|---|---|---|---|---|---|
Islam M [48] | Goh MJ [41] Kim G [40] Tran KT [65] Tsan YT [35] McGlynn KA [66] | January 1, 1990, and September 1, 2019 | case–control, Prospective cohort, retrospective cohort, nested cohort | 6 studies(Goh et al., Kim et al., McGlynn et al., Lai et al., Tsan et al., with 86,827 patients | Type 2 diabetes | The rate of HCC reduction was also significant among patients with diabetes (RR: 0.44, 95% CI: 0.28–0.70) |
Zhang J [57] | German MN [67] Lee TY [68] Pinyopornpanish K-1 [69] Pinyopornpanish K-2 [70] Zou B [71] | January 1, 2000 to February 27,2022 | case–control, and cohort | 5 studies (Lee et al., German et al., 2 studies by Pinyopornpanish et al., and Zou et al.) with 684,363 patients | MASLD | Statin use reduced the incidence of HCC in patients with MASLD (OR: 0.49; 95% CI, 0.33–0.73) |
Wang S [63] | Tseng CH [72] | to July 1, 2022 | retrospective or prospective cohort | 1 study (Tseng et al.) with 66,237 patients | Type 2 diabetes | Statin use reduced the risk of HCC in patients with type 2 diabetes (HR:0.46, 95% CI, 0.39–0.54) |